Characteristic | AD (n= 78) | aMCI (n= 59) | Normal Control (n= 66) | P* |
---|---|---|---|---|
Demographic | Â | Â | Â | Â |
   Age, y (mean, SD) | 75.7 (8.4) | 71.3 (8.5) | 71.1 (8.3) | 0.0005 |
   Female, N (%) | 47 (60%) | 28 (43%) | 24 (36%) | 0.017 |
   Education, y (mean, SD) | 11.4 (2.8) | 12.8 (3.5) | 13.1 (2.7) | 0.0005 |
Clinical | Â | Â | Â | Â |
   Statin Use, N (%) | 16 (21%) | 17 (28.8%) | 11 (17%) | 0.26 |
   BMI (mean, SD) | 25.4 (3.2) | 25.6 (3.9) | 24.6 (3.7) | 0.33 |
   ESC score (mean, SD) | 0.133 (0.110) | 0.094 (0.102) | 0.103 (0.078) | 0.015 |
   Diabetes type 1 or 2, N (%) | 6 (7.7%) | 1 (1.7%) | 3 (4.5%) | 0.30 |
   History of heart disease, N (%) | 8 (10.3%) | 9 (15.3%) | 7 (10.6%) | 0.68 |
   Hachinski score (mean, SD) | 2.6 (1.9) | 2.5 (2.6) | 0.7 (1.0) | < 0.0001 |
   Scheltens score (mean, SD) | 12.2 (9.9) | 10.8 (10.8) | 6.4 (5.7) | 0.0021 |
   Wahlund score (mean, SD) | 4.0 (2.7) | 3.7 (2.8) | 2.8 (1.7) | 0.04 |
   Duration of symptoms, y (mean, sd) | 2.5 (2.4) | 3.1 (3.3) | NA | 0.63 |
   MMSE, mean (mean, SD) | 23.8 (2.7) | 28 (1.7) | 29.1 (1.0) | < 0.0001 |
Laboratory | Â | Â | Â | Â |
   LpPLA2, nmol/min/ml (mean, SD) | 197.1 (38.4) | 205.5 (43.4) | 195.4 (41.9) | 0.34 |
   LDL, mmol/L (mean, SD) | 2.9 (1.0) | 2.9 (0.8) | 3.0 (1.2) | 0.79 |
   HDL, mmol/L (mean, SD) | 2.0 (0.5) | 1.8 (0.5) | 1.7 (0.5) | 0.005 |
   Total cholesterol:HDL ratio | 3.0 (0.9) | 3.2 (0.9) | 3.5 (1.2) | 0.012 |
   Homocysteine, Umol/L (mean, sd) | 15.1 (5.4) | 14.1 (7.9) | 12.3 (3.4) | 0.002 |
   HbA1c, % (SD) | 5.6 (0.4) | 5.6 (0.4) | 5.5 (0.3) | 0.43 |
CSF markers of AD | Â | Â | Â | Â |
   Aβ42, pg/ml (mean, SD) | 421.4 (147.6) | 568.2 (251.7) | 809.7 (260.5) | < 0.0001 |
   CSF T-Tau, pg/ml (mean, SD) | 698.5 (317.2) | 417.2 (245.6) | 308.0 (195.9) | < 0.0001 |
   CSF P-Tau, pg/ml (mean, SD) | 101.9 (58.0) | 62.9 (27.9) | 52.0 (21.6) | < 0.0001 |
Genetic | Â | Â | Â | Â |
   APOE ε4-positive, N (%) | 45 (58%) | 30 (50.5%) | 4 (6%) | NA†|